Pascal Lebray

ORCID: 0000-0001-8719-6533
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • Organ Transplantation Techniques and Outcomes
  • Hepatitis Viruses Studies and Epidemiology
  • Liver Diseases and Immunity
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Transplantation: Methods and Outcomes
  • Systemic Lupus Erythematosus Research
  • Diet, Metabolism, and Disease
  • Alcohol Consumption and Health Effects
  • Renal Transplantation Outcomes and Treatments
  • HIV/AIDS drug development and treatment
  • Systemic Sclerosis and Related Diseases
  • Pancreatitis Pathology and Treatment
  • Metabolism and Genetic Disorders
  • Polyomavirus and related diseases
  • Diet and metabolism studies
  • Heme Oxygenase-1 and Carbon Monoxide
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Eosinophilic Esophagitis
  • Viral gastroenteritis research and epidemiology
  • Endoplasmic Reticulum Stress and Disease
  • Healthcare Systems and Practices

Sorbonne Université
2015-2025

Pitié-Salpêtrière Hospital
2014-2025

Assistance Publique – Hôpitaux de Paris
2014-2024

Inserm
2002-2023

Centre de Recherche Saint-Antoine
2023

Sorbonne Paris Cité
2023

Fondation pour l’innovation en Cadiométabolisme et Nutrition
2015-2023

Hôpital Charles-Foix
2021

CHU Dijon Bourgogne
2021

Centre de recherche Translationnelle en Médecine moléculaire
2021

There is no established therapy for hepatitis E virus (HEV) infection. The aim of this retrospective, multicenter case series was to assess the effects ribavirin as monotherapy solid-organ transplant recipients with prolonged HEV viremia.

10.1056/nejmoa1215246 article EN New England Journal of Medicine 2014-03-20

Female sex is a protective factor for the progression of fibrosis in patients with chronic hepatitis C virus (HCV) infection. Experimental data suggest that estrogens may have an antifibrotic effect. The objective this study was to evaluate influence past pregnancies, oral contraceptives, menopause, and hormone replacement therapy (HRT) on liver HCV-infected women. Four hundred seventy-two women received survey regarding prior use contraceptives HRT. impact these variables its were evaluated...

10.1002/hep.20463 article EN Hepatology 2004-11-24

Abstract Background: FibroTest, a noninvasive method of measuring biomarkers liver fibrosis, is an alternative to biopsy for determining the severity chronic hepatitis C virus (HCV) infection. We compared 5-year prognostic value FibroTest with staging predicting cirrhosis decompensation and survival in patients HCV Methods: Fibrosis stage was assessed on same day by prospective cohort 537 patients. Disease classification at baseline 157 severe fibrosis (FibroTest >0.58), 137 moderate...

10.1373/clinchem.2006.070961 article EN cc-by Clinical Chemistry 2006-08-25

FibroTest and elastography have been validated as biomarkers of liver fibrosis in the most frequent chronic diseases screening patients with diabetes. One challenge was to use them for estimating prevalence fibrosis, identifying independent risk factors propose strategies general population. We prospectively studied 7,463 consecutive subjects aged 40 years or older. Subjects presumed advanced (FibroTest greater than 0.48) were re-investigated a tertiary center. The sample characteristics...

10.1186/1471-230x-10-40 article EN cc-by BMC Gastroenterology 2010-04-22

Abstract Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with HEV infection treated ribavirin monotherapy (N = 255), identify predictive factors SVR, and evaluate impact RNA mutations on response. Methods Data from 255 SOT 30 centers were analyzed. was given at median dose 600...

10.1093/cid/ciz953 article EN Clinical Infectious Diseases 2019-10-01

Abstract Background & Aims Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious phase studies. Real‐world data daclatasvir+sofosbuvir GT infection are presented from the French Temporary Authorisation Use programme, which allowed patients need without other options access to daclatasvir ahead of its market authorization. Methods Patients with F3/F4 fibrosis and/or...

10.1111/liv.13383 article EN cc-by-nc-nd Liver International 2017-02-08

Neurological and neuro-otological studies were carried out on 102 adults with mild cranio-cervical trauma productive of positional vertigo perilymph fistula as confirmed by laboratory tests, the finding at tympanotomy in surgically managed group. this patient group, all other neurological diagnoses excluded, e.g. epilepsy, cerebral palsy, multiple sclerosis, retardation; for group those a history ototoxicity, labyrinthitis, Meniere's disease, chronic car infections, or developmental familial...

10.3109/00016488909138632 article EN Acta Oto-Laryngologica 1989-01-01

Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold standard. Non-invasive techniques, stiffness measurements (LSM) and biomarkers [FibroTest(R) (FT)], are widely used in countries where they available. The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint vice versa. proof of concept taken the manufacturers recommendations for excluding patients at high risk false negative/positive. hypothesis that concordance between...

10.1371/journal.pone.0003857 article EN cc-by PLoS ONE 2008-12-03
Coming Soon ...